Search

Displaying results 301 - 310 of 10000 in total
  1. Drug

    Guanfacine

    go.drugbank.com/drugs/DB01018
    ApprovedInvestigational

    [L11277] Guanfacine was first described in the literature in 1974.[A189841] Guanfacine was granted FDA approval on 27 October 1986.[L11274] … Guanfacine, or BS 100-141,[A189838,A189841] is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension[L11274] but is now indicated as an extended release

    Products: Guanfacine ER, ARİSLOW ER 1 MG UZATILMIŞ SALIMLI TABLET, 7 TABLET
  2. Drug

    Levosulpiride

    go.drugbank.com/drugs/DB16021
    Investigational

    Products: ENDACINE 25 MG SOLUCION EN GOTAS, LEVOSULPIRIDE EG
  3. Drug

    Dinoprostone

    go.drugbank.com/drugs/DB00917
    ApprovedInvestigational

    Dinoprostone is a naturally occurring prostaglandin E2 (PGE2). It has important effects in labour. It also stimulates osteoblasts to release factors which stimualtes bone resorption by osteoclasts.

    Categories: Prostaglandins ESynonyms: (15S)-prostaglandin E2, Prostaglandin E2
  4. Indication

    Acute Duodenal Ulcers

    go.drugbank.com/conditions/DBCOND0080549
    Drugs: Famotidine
    Synonyms: DU, DU - Duodenal ulcer
  5. Drug

    Pyrantel

    go.drugbank.com/drugs/DB11156
    ApprovedVet approved

    Pyrantel is on the World Health Organization's List of Essential Medicines, which are the safest and most effective medicines required in a functioning health system [L1901], [L1902]. … Pyrantel was initially described in 1965 by researchers from Pfizer who sought cyclic amidines with suitable pharmacokinetic properties (specifically, duration of action) for use as an anthelmintic drug

    Mixtures: PAMOATO DE PIRANTEL/PAMOATO DE OXANTEL SUSPENSION, PAMOATO DE OXANTEL 250 MG/5ML + PAMOATO DE PIRANTEL 250 MG/5 ML SUSPENSIÓN.Products: PIREL® TABLETAS DE 250 MG, PAMOATO DE PIRANTEL SUSPENSION
  6. Drug

    Fluticasone propionate

    go.drugbank.com/drugs/DB00588
    ApprovedInvestigational

    Fluticasone propionate was first approved in 1990[L5962].

    Mixtures: DYMISTA D, SERETIDE FORTE50/500UG DProducts: FLUTIDE FORTE 500 DISKU ED, FLUTIDE MITE 100 DISKUS ED
  7. Drug

    Magnesium sulfate

    go.drugbank.com/drugs/DB00653
    ApprovedInvestigationalVet approved

    A small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. … It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions.

    Mixtures: ELETTROLITICA DI REINTEGRAZIONE CON GLUCOSIO E SODIO GLUCONATO FKI, ELETTROLITICA DI REINTEGRAZIONE CON GLUCOSIO E SODIO GLUCONATO FKIProducts: Sel D Epsom, Magnesium Sulfate in Water
  8. Drug

    Nitric Oxide

    go.drugbank.com/drugs/DB00435
    ApprovedInvestigational

    This gas is an important signaling molecule in the body of mammals including humans and is an extremely important intermediate in the chemical industry. … It reacts with the ozone in air to form nitrogen dioxide, signalled by the appearance of the reddish-brown color.

    Mixtures: Mezcla de óxido nítrico/NitrógenoCategories: Compounds used in a research, industrial, or household setting
  9. Drug

    Ephedra sinica root

    go.drugbank.com/drugs/DB01363
    ApprovedNutraceutical

    The sale of ephedra-containing supplements intended to increase muscle weight or promote weight loss was banned in the United States in 2004 due to the risk for adverse effects and a lack of evidence for … The drug is still sold in Canada in OTC formulations for respiratory conditions associated with bronchial asthma.

    Mixtures: Dr. Miller's Formula No. 1Synonyms: Ma huang gen (ephedra sinica)
  10. Drug

    SARS-CoV-2 Sclamp

    go.drugbank.com/drugs/DB15849
    Investigational

    The University of Queensland (UQ), in partnership with The Coalition for Epidemic Preparedeness Inovations (CEPI) and CSL has developed a COVID-19 candidate, SARS-CoV-2 Sclamp. … The SARS-CoV-2 Sclamp Vaccine was developed within 3 weeks and moved immediately into preclinical testing through partnership with Dutch company, Viroclinics Xplore.

    Synonyms: UQ-1-SARS-CoV-2-Sclamp, SARS-CoV-2 Sclamp adjuvanted vaccine